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Normal human serum also contains the lymphotoxin found in
minimal change nephropathy
NAPIER M. THOMSON and NORBERT KRAFT
Department of Nephrology, Prince Henrys Hospital, Melbourne, Australia
Normal human serum also contains the lymphotoxin found in minimal
change nephropathy. We have studied serum—borne lymphotoxic activ-
ity in a large patient group with various forms of glomerulonephritis
(GN). A potent inhibitor of lymphocyte blastogenesis was frequently
demonstrable not only in patients with active minimal change nephrop-
athy as has been previously described, but also in other forms of GN.
The inhibitor was resistant to heating and prolonged storage but
rendered ineffective by normal serum. We have been able to show for
the first time, using gel filtration, that normal serum also contains the
inhibitor. The inhibitor was shown to be highly avid for a receptor on
leucocytes as judged by dose response experiments and by the ability of
cell pellets to remove this activity. Gel filtration demonstrated a
molecular weight in the range 60 to 160 kilodaltons. The combination of
information regarding the biological properties of the inhibitor, its
clinical occurrence and molecular weight suggests it to be distinct from
any other well—described lymphotoxin. It's presence in normal serum in
association with a self-regulatory factor and the known proclivity of
minimal change nephropathy patients to infection, also indicate that the
inhibitor may play an important role in immunoregulation.
Although it is generally accepted that most cases of glomer-
ulonephritis are the consequence of glomerular reactive anti-
body or circulating immune complexes [I], cell mediated
immunity (CMI) may also play a role, either augmenting
humoral—based glomerular injury or acting as the prime immu-
nological event [2]. CMI has been particularly implicated in the
genesis of minimal change nephropathy (MCN) [3, 4] and it has
even been postulated that the disease is a consequence of a
persistent clone of T cells which produces a circulating
lymphokine, which is injurious to the glomerular basement
membrane (GBM) [5]. In 1976 Moorthy, Zimmerman and
Burkholder reported that the plasma of patients with the
nephrotic syndrome due to MCN inhibited the phytohemag-
glutinin (PHA)—induced or mixed lymphocyte reaction (MLR)—
induced blastogenic response of autologous and heterologous
lymphocytes, and that this effect was specific for MCN [6]. The
findings of Moorthy have been confirmed [7, 81 but further
studies, including our own, have indicated that inhibition may
also be induced by serum from patients with the nephrotic
syndrome due to other causes [2, 9—13]. It is therefore possible
that the inhibitory effect of nephrotic sera may be a conse-
quence of the nephrotic state and may not be involved in the
pathogenesis of MCN.
We have conducted further studies on the inhibitor in order to
better our understanding of its properties and mechanism of
action—neither of which have been well characterized. A
further series of patients (N = 137) with glomerulonephritis of
various types were examined for the presence of inhibitory
activity and mate—responsiveness to PHA. The effect of the
inhibitor on a series of leucocyte/leukemic cell lines was deter-
mined and a number of basic physico-chemical characteristics
have been established. These studies lead us to suggest that the
inhibitor is also present in normal sera, but its activity is
masked by a counterfactor (CF). The appearance of inhibitory
activity in nephrotic sera is thus ascribed to the loss of CF,
which is demonstrably more sensitive to heating than the
inhibitor itself.
Methods
Patients
Peripheral blood lymphocytes (PBL) and serum were ob-
tained from 137 patients and 25 normal controls. The type of
glomerulonephritis (Table 1) was determined in all cases by
renal biopsy, with evaluation by light, immunofluorescent and
electron microscopy. Blood samples were taken during active
and inactive phases of disease, as determined by the presence
or absence of the clinical states of nephrotic syndrome, ne-
phritic syndrome or active systemic disease. All initial samples
were obtained before the use of therapeutic agents (corticoste-
roids, immunosuppressives, diuretics). Patients with a creati-
nine clearance of less than 25 ml/min were excluded.
Lymphocyte preparation
PBL were isolated on hypaque ficoll solution and stimulated
with PHA as described previously [141. The medium used was
RPMI (Gibco Laboratories, Grand Island, New York, USA)
containing 10% fetal calf serum (Flow Labs, Helsinki, Finland).
Human leucocyte/leukemic cell lines were grown in the same
medium. Inhibitory activity was assessed by including 12.5% of
patient serum or fractions obtained by Sephacryl S300 separa-
tion.
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Serum fractionation by Sephacryl S300
Five milliliter samples of sterile, filtered human serum were
fractionated aseptically on a 35 mm x 850 mm column of
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Table 1. Type of glomerulonephritis
% PHA response with
PHA response in FCS autologous serum &
CPM/cell FCSa
Patient category N Mean SEM N Mean SEM
Normal 25 1.35 0.16 17 98.1 4.3
Minimal change nephropathy
Nephrotic 11 0.66 0.17 11 38.6 8.6
In remission 19 1.34 0.33 19 97.3 5.3
Membranous G.N.
Nephrotic 16 1.10 0.40 16 81.0 4.2
Non-nephrotic 4 1.23 0.10 4 91.5 2.6
FGS
Nephrotic 5 0.93 0.21 5 75.7 7.8
Non-nephrotic 5 1.58 0.56 5 111.8 4.9
Mesangioproliferative
Nephrotic 2 1.37 — 2 109 —
Non-nephrotic 11 1.50 0.23 11 73.5 24.6
Membrano-proliferative GN
Nephrotic 2 1.15 0.38 2 37 —
Non-nephrotic 5 1.15 0.52 5 107 20.8
Amyloid—nephrotic 1 0.84 — 1 58 —
Penicillamine GN
Nephrotic 2 1.83 — 2 72 —
Diabetic nephropathy
Nephrotic 5 1.11 0.57 3 72.5 11.9
Non-nephrotic 1 0.68 — 1 92 —
IGA Disease
Nephritic 1 1.08 — 3 52.8 21.4
Non-nephritic 24 1.31 0.19 20 97.3 4.7
SBE nephritis 2 1.23 — 2 103 —
Microscopic polyarteritis
Active 14 1.08 0.54 12 55.9 11.4
Inactive 4 1.18 0.21 4 102.1 2.6
S.L.E.
Active 3 0.66 0.04 3 51 12.4
Inactive 5 0.98 0.09 5 108 6.1
Wegeners granulomatosis 3 0.93 0.40 3 71 27.9
Anti-GBM GN 3 1.10 1.23 3 96 8.1
Scleroderma 1 0.79 — 1 122 —
Percent response calculated with respect to the PHA response in FCS containing medium. CPM = counts per minute of tritium label; SEM =
standard error of the mean
sephacryl S300 (Pharmacia Diagnostics, Uppsala, Sweden) at a
flow rate of 1 mI/mm at 15°, in phosphate—buffered saline pH
7.2. Fractions were collected automatically and were pooled to
contain the major protein peaks. The pools were freeze dried,
dissolved in minimal volumes of water, dialyzed against PBS at
4° for four hours, and adjusted to 5 ml. They were then filtered
through 0.2 i disk membranes and stored at —20°C.
Absorption of inhibitor by cells
Inhibitory fractions from sephacryl S300 separations were
incubated with approximately equal volumes of cell pellets for
30 minutes at room temperature. The inhibitory activity of the
supernatant obtained after centrifugation at 900 g for seven
minutes was compared with the unabsorbed fractions.
Statistics
Statistical comparisons were made by using Student's (-test
and the significance of the correlation was also evaluated by
using Student's (-test.
Results
Inhibitory patient serum factors
Sera from eight of 11 MCN patients added to autologous
lymphocytes undergoing a PHA response in the presence of
10% FCS caused suppression of the response (P < 0.01) (Fig.
1). Normal sera similarly added to autologous lymphocytes did
not inhibit the PHA response significantly. The inhibitory
activity of sera of the MCN patients during corticosteroid
induced remission was no longer significant, but reappeared
during relapse. Other patients with nephrotic syndrome due to
other disorders also had inhibitory activity in a smaller propor-
tion of cases (Table 1). These disorders included diabetic
nephropathy (2 of 5 cases with > 50% inhibition), IgA disease (1
of 3), SLE (2 of 3), membranoproliferative GN (1 of 2) mem-
branous nephropathy (1 of 16). Inhibitory serum activity was
not, however, confined to patients with nephrotic syndrome, as
several patients who had active glomerulonephritis and who
were not nephrotic did have inhibitory sera. These included
patients with proliferative GN of SLE (2 of 3), renal amyloido-
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Fig. 1. Inhibitory effects of autologous serum on the PHA response in
patients with minimal change nephropathy (MCN), inembranous GN
and microscopic polyarteritis. Mean response of normal donors or
patients in remission (El) or in patients with nephrotic syndrome () or
with active microscopic polyarteritis (). Error bars indicate strandard
error of the mean, N values as in Table I.
sis (1 of 1), Wegeners granuloniatosis (1 of 3), post-streptococ-
cal GN (1 of 1) and necrotizing GN of microscopic polyarteritis
(6 of 12).
The specificity of the inhibitory effect was examined by
testing 16 inhibitory sera from nephrotic patients and seven
inhibitory sera from non-nephrotic patients on normal donor
cells, All but one (from a patient with polyarteritis) of these
were again inhibitory, while 12 patient sera which were non-
inhibitory of autologous lymphocytes were also non-inhibitory
when tested against heterologous lymphocytes. The addition of
2-mercaptoethanol to the culture system at a concentration of 5
x l0— M failed to reverse the inhibitory effect of sera on
mitogen response.
Lymphocyte responses in the absence of autologous serum
In order to determine the intrinsic PHA response of patient
lymphocytes, these cells were washed repeatedly in PBS in
order to remove the human serum and then stimulated with the
mitogen in the presence of 10% FCS. Although lymphocytes
from normal donors gave a wide range of blastogenic responses
(Fig. 2), cells from patients with active MCN gave significantly
lower responses (P < 0.01). Once the nephrotic syndrome of
MCN was in steroid—induced remission and the patients were
no longer receiving steroids, the PHA response came back to
the normal range in all but two of 19 patients (that is, within 2
SD of the normal mean). While samples from some patients with
other categories of GN with nephrotic syndrome or other forms
of active disease had reactions below the normal range, no
other disease group had significantly lowered responses.
Fractionation of inhibitory and normal sera
Sephacryl 300 gel separation of inhibitory sera from patients
with MCN revealed the inhibitory activity to be in fractions of
molecular weight 60 to 160 kilodaltons (Fig. 3A). However
fractionation of non-inhibitory sera from normal subjects (N =
6) also revealed inhibitory fractions of similar range of molec-
ular weight (Fig. 3B).
Effects of serum inhibitor on human leucocyte—derived
cell lines
A potential explanation for the inhibition of PHA responses
by serum samples was the presence of glycoprotein which
competed for the mitogen. A number of spontaneously repli-
cating, human leucocyte—derived cell lines were therefore incu-
bated with the inhibitory sera, and tested for the capacity to
take up tritiated thymidine as an index of spontaneous cell
division. Table 2 shows one experiment where an inhibitory
fraction obtained from a normal serum sample was tested on
cell lines of various lineages. Similar effects were obtained on
repeated occasions with inhibitory fractions obtained from
normal or patient sera and with whole inhibitory sera. Cell lines
were not inhibited by normal sera or by gel separation—fractions
which did not inhibit the PHA response (data not shown). These
cell lines were subsequently used as a convenient source of
cells for quantitative estimations of inhibitor and counterfactor
activity.
Quantitation of inhibitor and the presence of a
counter factor (CF)
Inhibitory sera or fractions from gel separation experiments
yielded very steep dose—response curves when tested with the
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Fig. 2. PHA response in patients with minimal change nephropathy
compared with normals, membranous GN and microscopic polyarter-
ills. The cells were cultured in medium with 10% FCS. Human serum
was not present. Symbols are the same as Figure 1.
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Fig. 3. Distribution of inhibitory activity following S300 sephacryl gel
filtration. The plain line indicates % transmission at 280nm. The dotted
line indicates the positions of the fraction pooled and the solid line
(—•—) inhibitory activity measured with a PHA response. Pool I
includes 1gM; 2 alpha macroglobulin, 3 IgA; 4 albumin; 6, 7 & 8 contain
small polypeptides. A. Sample from a normal donor. B. Sample from a
patient with minimal change nephropathy. Pools were adjusted to the
original serum volume following freeze drying and dialysis.
PHA blastogenesis assay or with spontaneously dividing cell
lines (Fig. 4). Comparison of dilution curves obtained for
different serum samples also indicated that such curves may be
the basis of a quantitative analysis of inhibitory activity. For
example, a unit of inhibition might be defined as the activity
required to give 50% inhibition of thymidine incorporation of
20,000 cells of a given line (such as HSB2) during a four hour
culture period. The dose response curves suggest the presence
of a receptor for the inhibitory substance. Further evidence for
a receptor was provided by the ease with which the inhibitory
activity was removed from inhibitory fractions by absorbing
with pellets of leucocyte cell lines such as Nalm-6 or Cess B
(90% of activity absorbed by a single absorption) (Fig. 4). The
steep dose curve also suggests the receptor is of high affinity.
Counter factor activity was discovered following the finding
that normal sera also had inhibitory activity when separated on
gel filtration. Inhibitory fractions were therefore mixed with
unseparated normal serum in order to determine the presence of
a putative counter factor. This was readily demonstrable as
indicated in Figure 5, where 4 j.d of fresh normal serum when
Cell line Cell lineage
Control
response
Response in
presence of
inhibitor
B 85 B 7239 371 82 17
RPMI 8402 B 9548 793 76 18
DAUDI B 111306 281 135 15
NALM 6 Pre-B 5737 180 56 25
REH Null 7581 502 33 17
KM3 Null 5580 446 164 3
RC2A Macrophage 35396 771 65 27
U937 Macrophage 218808 4538 63 19
HSB2 T 9768 191 226 96
HPB MLT T 101264 2176 135 39
MOLT 4 T 34184 744 132 21
50,000 cells were incubated overnight in 200 d flat bottomed micro-
titer tray wells in tissue culture medium containing 10% FCS, 6 rl ofan
inhibitory fraction (following sephacryl S300 separation, freeze drying,
dialysis against PBS and adjustment to serum volume applied to
column), in a final volume of 100 l. Means of counts per minute
(quadruplicates) are indicated with standard error of the mean values.
added to an inhibitory fraction prior to incubation with the
leucocytes is seen to completely abrogate the activity of an
inhibitory sample, which in the absence of normal serum gives
55% inhibition in the assay. Again this effect is titratable, as
shown in Figure 6 where fresh serum samples from three
patients with glomerulonephritis whose sera were either non-
inhibitory or minimally inhibitory were compared for their
capacity to counteract an inhibitory aliquot which gave 100%
inhibition in the absence of human serum. These data indicate
not only that counter factor activity is quantifiable, but that
large differences may be expected in such measurements be-
tween patient samples.
Further characterization of the inhibitor and counterfactor
The inhibitor was not absorbed by chromatography on
sepharose—protein A or on sepharose-Con A columns, as >90%
of the activity applied was recovered in the eluates. The
inhibitor is therefore unlikely to be an IgG molecule or possess
glucose or mannose residues. The inhibitor was resistant to heat
(>90% activity was retained after 30 mm at 56°C) and retained
activity for six months at —20°C. The inhibitor was not a VLDL
or LDL as it was able to enter a solution of isopaque ficoll in
phosphate buffered saline (1.063 g/ml) on ultracentrifugation,
nor did serum inhibitor levels correlate with serum lipid con-
centrations (r < 0.4). There was no significant correlation with
serum albumin (r < 0.4) in MCN patients with nephrotic
syndrome. However, for patients with membranous GN with
nephrotic syndrome there was a marginally significant correla-
tion between the degree of inhibition and the serum concentra-
tion of albumin (r = 0.49, P <0.05). The counterfactor activity
of unfractionated sera was completely lost on heating at 56° for
30 minutes and following storage at —20°C for six months. In all
experiments demonstrating counterfactor activity in sera, fresh
sera were used.
Discussion
These studies have confirmed that sera from patients with
nephrotic syndrome due to minimal change nephropathy are
inhibitory to mitogen induced blastogenesis of autologous and
A Table 2. Effects of inhibitor on spontaneous cell line division
0)
CO
0a(00)
0
00
B
100
50
'1)
COC0a
CO0)
0
C00
C0
CO
CO
E
CC)50
CO
I-
C0
CO0)
E
CO
C
CO
I-.
at
Pool number
1190 Thomson and Kraft
heterologous lymphocytes and spontaneous division of human
lymphoblastoid cell lines, and that this inhibitory effect is lost
when patients are in remission. However unlike the initial claim
by Moorthy et al [61, we, like others [9, 10, 12, 13], have shown
that inhibition is not specific for MCN but may also be found in
sera of some patients with nephrotic syndrome due to other
types of GN. Thus, inhibitory sera were found in patients
having membranous glomerulopathy, focal and segmental hya-
linosis/sclerosis, diabetes, membranoproliferative GN, mesan-
gioproliferative GN with IgA deposits, renal amyloidosis and
SLE. However, the degree of suppression induced by sera from
patients with NS due to MCN was significantly greater than that
of sera from patients with membranous GN. Although the mean
serum albumin concentration was higher in patients with mem-
branous GN than MCN, the difference in inhibitory activity was
still quite significant in patients with comparable serum—
albumin concentrations. However, like several other groups
and unlike Taube et al [13], we were unable to show a
correlation between the degree of hypoalbuminemia in MCN
and the severity of lymphocyte suppression, although we did
find a marginally significant (P < 0.05) correlation in nephrotic
patients with membranous GN.
The PHA response of lymphocytes in the absence of autolo-
gous serum was also significantly depressed in patients with NS
due to MCN compared to patients with NS due to membranous
GN or to normal donors. Other groups have also reported
depressed PHA response by lymphocytes from patients with
active MCN in the absence of autologous serum, although the
degree of depression has varied considerably from series to
series. Tomizawa et al [7] found a mean depression of 50% (in
20—
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Fig. 4. Steep dose—response curve of inhibition induced by inhibitory
fraction on spontaneous cell division (-•). Also shown is activity of
inhibitory fraction after absorption. A sephacryl S300 inhibitory frac-
tion was added overnight to cultures of Daudi cells and spontaneous cell
division assessed by tritiated thymidine incorporation. An aliquot of the
fraction was also absorbed twice with an equal volume of Cess-B cells
and was similarly assayed for inhibitor activity. Symbols are: original
fraction (-•-); after 1st absorption (-0-); after second absorption (-0-).
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Fig. 5. Normal serum counteracts inhibitor. 2.5 al of inhibitory frac-
tion added to HSB2 cells in cultures which contained 10% FCS as well
as various amounts of normal human serum. 20,000 cells were incu-
bated overnight and tritiated thymidine incorporation was assessed.
Comparison is made with the response obtained in medium containing
10% FCS.
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Fig. 6. Comparison of counterfactor activity of sera of patients with
glomerulonephritis whose sera were non-inhibitory or minimally inhib-
itory. 12.5 lof inhibitory fraction was added to PBL undergoing a PHA
response in medium containing 10% FCS and varying amounts of serum
from three patients: 0, 0. Open dots indicate the response in the
presence of patient serum plus 10% FCS; solid dots the response in the
presence of the inhibitor, 10% FCS plus the indicated amounts of
patient sera.
the presence of normal plasma), Minchin, Turner and Bower [8]
a mean depression of 30%, while Sasdelli et al [11] found the
response to be reduced by 30% or more in only 50% of patients.
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However, litaka and West [9] found responses to be normal.
Such discrepancies might be explained by the considerable
variation between laboratories in the technique of mitogen
stimulation of lymphocytes. We have routinely used optimal
concentrations of PHA. Our results are not due to inadequate
washing of serum from lymphocytes. We suggest the suppres-
sion of lymphocyte responses obtained in the absence of
autologous serum may be a function of the considerable avidity
of the inhibitor for a cell surface receptor, the repeated wash-
ings carried out being insufficient to completely remove the
inhibitor acquired in vivo. litaka et al [91 showed that a brief
incubation of four hours of lymphocytes with inhibitory sera
resulted in inhibition which could not be prevented by washing
and subsequent incubation with normal serum. Further evi-
dence of the high avidity of inhibitor(s) comes from our obser-
vation that 90% of inhibitory activity of serum is removed from
serum by incubation with lymphocytes or with lymphoblastoid
cell lines and the steep dose—response curve.
Although, as groups, patients with NS due to membranous
GN or FGS did not show a significant reduction of lymphocyte
responses in the absence of autologous serum, three patients
with NS due to MGN and two due to FGS, one with diabetes
and three patients with SLE did show poor lymphocyte re-
sponses. Thus, neither a reduction of lymphocyte response nor
inhibition of lymphocyte responses by serum were specific for
NS due to MCN compared to NS due to other types of GN.
However it would seem that quantitatively, inhibitory activity
is greater in serum from patients with NS due to MCN.
The nature of the inhibitory activity of nephrotic serum has
previously been only superficially studied. litaka et al [9] found
inhibitory activity to be heat stable, not removable from cells by
washing (suggesting strong avidity), not reversible by addition
of 5% normal serum, not lymphocytolytic; they suggested that
the cell surface receptors for inhibitor may normally be masked
by a substance in normal serum. Tomizawa et al [7] also found
inhibitory activity to be heat stable and found inhibitory activity
to be in both the permeable and non-permeable fractions of
colloidal bag dialyzates. Unlike litaka et al [9], Martini et al [12]
found that inhibitory activity could be largely overcome by the
addition of NHS. We have found that inhibitory activity is heat
and cold stable, avidly absorbed by incubation with lympho-
blastoid cell lines, and not removed by ultracentrifugation,
indicating that the activity is not due to immune complexes. In
addition, the failure of 2-mercaptoethanol to reverse inhibition
indicates that inhibition is not due to interference with
macrophage cooperative function, as this compound has been
previously shown to substitute for the requirement for macro-
phages in the mitogen response [14]. Moreover, nephrotic sera
inhibited the spontaneous division of all lymphoblastoid cell
lines tested (including B, T, null, myeloid leukemia—derived
lines), a situation obviously independent of macrophages. We
also found that inhibitory activity of nephrotic sera could be
blocked by the addition of 10% normal human serum while
non-inhibitory sera from patients with mild nephrotic syndrome
were less effective in reversing the activity of inhibitory sera.
This suggested that the inhibition was not necessarily related
just to the presence of an inhibitor, but perhaps also to the
presence/absence of a factor which was counteractive to the
inhibitor. The system used to detect serum inhibitory activity
was a comparison of responses with FCS alone and FCS plus
inhibitory sera. Therefore inhibition cannot be explained by a
deficiency of an essential element in the inhibitory sera. How-
ever the possibility that inhibitory sera lacked a counteracting
factor (acting on the inhibitor itself) remained.
Fractionation of inhibitory sera according to molecular size
revealed inhibitory activity to be present in fractions of molec-
ular weight ranging from 60 to 160 kilodaltons. These inhibitory
fractions had identical characteristics to the inhibitory activity
of whole serum: they were heat and cold stable, avidly ab-
sorbed by lymphoblastoid cells and could be reversed by the
addition of 10% NHS. The degree of inhibition induced by the
fractions was much greater than that of whole inhibitory serum
in that inhibition was only lost by an 80-fold dilution of
inhibitory fraction. Fractionation of normal non-inhibitory sera
revealed similar inhibitory fractions as those present in inhibi-
tory sera, the inhibitory activity of which could again be
reversed by the addition of 10% NHS and in one instance could
be reversed by the addition of the albumin fraction of the
normal serum. Thus, we believe that the inhibitory activity of
nephrotic sera is due to the presence of an inhibitory factor(s)
normally found in serum, but which is counteracted by another
factor(s) present in normal serum. It is hypothesized that in
nephrotic patients, counteractive factor is lost (perhaps in the
urine). It may be possible to recover the counterfactor from
urine, although it is possible that the filtered counterfactor may
be reabsorbed and metabolized by the tubule. The molecular
weight of the counteractive factor has not been determined but
the experiment in which the albumin fraction counteracted the
inhibitor suggested that the counteractive factor to be of MW
around 60,000 daltons. It could be argued that in the NS not
only would the counteractive factor be lost in the urine but also
the inhibitory factor itself. This may be so and the actual degree
of inhibitory activity will depend on the relative proportions of
inhibitor and counteractive factor remaining in the circulation.
The nature of the balance of the inhibitory and counteractive
activity in normal serum is the subject of current investigations.
It is pointed out that the capacity of 10% NHS to reverse
inhibition in vitro suggests that the counterfactor is usually in
excess in normal serum. In fact, it is readily demonstrable that
the counterfactor in normal and patient sera is titratable against
inhibitor and that increasing the dose of the inhibitor in these
titrations displaces the inhibition curve in an appropriate man-
ner. It is possible that the counteractive factor acts as a carrier
of inhibitor and the resultant complex is itself noninhibitory, or
that the counterfactor competes for the same receptor as the
inhibitor (but at a lower affinity as suggested by litaka and West
[9]). Only when there is a relative deficiency of the counterfac-
tor would the inhibitory factor be expected to have biological
effects.
It has been known for a number of years that normal serum
contains immunosuppressive factors [15] which include alpha
glycoproteins [16], immunoregulating globulin [17], an alpha-2-
macroglobulin [18, 19] alpha fetoprotein [20], a subclass of low
density lipoprotein called LDL inhibitor [21], VLDL [22—241
and C-reactive protein [25]. Other, more recently described
factors include Uromodulin (a 75 kd immunosuppressive glyco-
protein from the urine of pregnant women [261) and a variety of
substances obtained from the sera of patients with various
forms of cancer [27—32] or viral infections [33]. Most of these
factors appear distinct from the inhibitor we have described on
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the basis of molecular weight and the specificity of reaction with
various target cell lines. However, several inhibitors have not
been sufficiently described to permit definitive comparisons to
be made and this is worthy of further investigation. Although
the suppressive effect of LDL-In can be prevented by the
addition of normal human serum 1241 its molecular weight is 2.6
million daltons, much higher than the value for the inhibitor we
have described. Naturally—occurring serum inhibitory factors in
the molecular weight range of the inhibitor we have described
include immunoregulatory globulin, alpha fetoprotein and C-
reactive protein. These substances are not increased in concen-
tration in nephrotic syndrome. Some of the most profoundly
inhibitory sera were found in patients with polyarteritis with
GN but without NS. These patients all had active disease and
had high serum concentrations of C-reactive protein and im-
mune complexes. C-reactive protein has been shown to bind
selectively to human T cells and inhibit their ability to form E
rosettes and react in the MLR [25]. It would therefore seem
likely that this protein was responsible for the inhibition ob-
served in cases of GN associated with polyarteritis. Similarly it
is possible that serum inhibition in our patients with amyloido-
sis who were also nephrotic may be explained in part by the AA
protein [34] and that of SLE patients by non-cytotoxic
antilymphocyte autoantibodies [35].
Thus the mechanism of serum induced inhibition of mitogen
responses in patients with GN will depend on the presence or
absence of nephrotic syndrome and also on the presence of
other inhibitors associated with other disease processes which
precipitate this syndrome. The clinical significance of inhibitory
serum in patients with GN is unknown. Our data and that of
others provides no evidence that the serum inhibitor plays any
role in the initiation of MCN or in the modulation of a putative
pathogenic T-lymphocyte clone which is thought to induce
glomerular capillary permeability [5]. On the contrary, all the
evidence indicates the inhibitor to be a consequence of the
nephrotic state. The poor mitogen responses of freshly—har-
vested patient lymphocytes indicates that the inhibitor may be
of clinical significance by affecting the patient's capacity to
combat infections. Prior to the introduction of antibiotics, more
than 50% of MCGN patients died within one year from infec-
tions, especially from pneumococcal peritonitis, which further
suggests that this patient group is strongly immunocompro-
mised.
It is apparent that further progress in this area is highly
dependent on the ability to discriminate between the various
inhibitory factors known to be present in human serum. Current
work is therefore aimed at purifying the inhibitor described
here, for further detailed study and for the purpose of setting up
a radioimmunoassay for identifying its presence in the sera of
different patient groups. As this is the first instance of this
inhibitor being described in normal serum samples, some spec-
ulation is perhaps warranted as to its usual physiological
function. The presence of excess counterfactor in all normal
serum samples examined by us suggests that the inhibitor does
not act in the circulation but may be called into action else-
where, One possibility is local inflammatory sites where, with
increased vascular permeability, there is exudation of serum
proteins. In this setting the secretion of large amounts of
hydrolytic enzymes by myeloid cells may well be inimical to the
existence of the counterfactor to a greater extent than to the
inhibitor, thereby potentiating the activity of the latter and
acting as a feedback control system on the local immune
response.
Reprint requests to Norbert Kraft, M.D., Department of Nephrol-
ogy, Prince Henry's Hospital, St. Kilda Road, Melbourne 3004, Aus-
tralia.
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